Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor

September 3, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search